Xarelto Takes Lead In Exploiting VTE Market Opportunity
Executive Summary
J&J/Bayer’s Xarelto currently has the broadest label among new anticoagulants, with a new indication in the U.S. for venous thromboembolism. But Bristol/Pfizer’s Eliquis is also being positioned for broader use in VTE, with positive data reported at the American Society of Hematology meeting in December.
You may also be interested in...
Daiichi Sankyo’s Edoxaban Steps Up As Once-Daily Competitor To Xarelto
Daiichi Sankyo plans to file two once-daily doses of the edoxaban for stroke prevention in atrial fibrillation, but the lowest one was associated with more ischemic strokes compared to warfarin in the ENGAGE AF-TIMI 48 study, which could limit prospects for use.
Daiichi’s Edoxaban Steps Up As Once-Daily Competitor To Xarelto
Daiichi Sankyo plans to file two once-daily doses of the edoxaban for stroke prevention in atrial fibrillation, but the lowest one was associated with more ischemic strokes compared to warfarin in the ENGAGE AF-TIMI 48 study, which could limit prospects for use.
Eliquis Poised To Wake Up U.S. Oral Anticoagulant Market
Bad press and lawsuits related to bleeding events for Boehringer Ingelheim’s novel anticoagulant Pradaxa create a window of opportunity for Eliquis, which is pending approval in the U.S. and could have what it takes to tip the market away from generic warfarin.